Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update.
Hansoh Pharmaceutical has received Breakthrough-Therapy-Designated Drug status from China’s National Medical Products Administration for HS-20093, a self-developed B7-H3-targeted antibody-drug conjugate for injection. The proposed indication is for patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma who have failed first-line platinum-based chemotherapy and immune checkpoint inhibitor treatment.
The designation highlights regulatory recognition of HS-20093’s potential clinical benefit in a hard-to-treat cancer setting, and may accelerate its development and review timeline. This could strengthen Hansoh’s position in the oncology biologics and ADC segment, expand its late-stage pipeline, and potentially offer a new treatment option to ESCC patients with limited therapeutic alternatives.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company focused on the research, development and commercialization of innovative drugs. The group develops oncology and other specialty medicines, leveraging in-house R&D capabilities and targeting major unmet medical needs in the domestic and potentially broader Asian healthcare markets.
Average Trading Volume: 9,352,240
Technical Sentiment Signal: Buy
Current Market Cap: HK$219.8B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.